Fierce Biotech1 min read
saveMerck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
Merck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
comments(0)
5-min edit window · permanent after that